MAPT and Alzheimer disease: Moreover, the improved cognitive function induced by KEN in animal models also involves a reduced Tauopathy that might be irrespective of SHMT2, as KEN is an inhibitor of GSK and CDKs that are known to phosphorylate Tau.[58] Thus, the detailed function of SHMT2 in the pathophysiology of AD remains to be clarified in the future.